Close Menu

NEW YORK – The GenomeWeb Index rose nearly 15 percent in the first half of 2020, largely on the strength of companies that developed diagnostic tests for SARS-Cov-2 who have seen their stocks surge during the pandemic.

The index outperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which fell nearly 10 percent, rose 12 percent, and rose nearly 14 percent, respectively, in H1 2020. Individual stock performances in the GenomeWeb Index were largely positive in H1, as 25 of the 32 stocks saw gains and only seven saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.